Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.38 |
| ▸ | PDE9A | O76083 | 12/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL212878 | 0.96 | PNP (0.37) | PNPPDE9AADORA2APIK3CAMTOR | |
| SCHEMBL214634 | 0.87 | PDE9A (0.45) | PNPPDE9A | |
| SCHEMBL2735199 | 0.87 | ALDH1A1 (0.42) | PNPPDE9AADORA2AALDH1A1PIK3CA | |
| SCHEMBL214504 | 0.86 | PNP (0.43) | PNPPDE9AADORA2AALDH1A1KDM4E | |
| SCHEMBL2735190 | 0.85 | PNP (0.42) | PNPPDE9AADORA2AALDH1A1KDM4E | |
| SCHEMBL212571 | 0.84 | PNP (0.42) | PNPPDE9AALDH1A1KDM4EMEN1 | |
| SCHEMBL212290 | 0.84 | PNP (0.42) | PNPPDE9AALDH1A1KDM4EHPGD | |
| SCHEMBL2735152 | 0.82 | KDM4E (0.46) | PDE9AALDH1A1MAPK8MAPK10KDM4E | |
| SCHEMBL213267 | 0.82 | KDM4E (0.43) | PNPPDE9AALDH1A1KDM4EMEN1 | |
| SCHEMBL8286854 | 0.82 | PNP (0.40) | PNPPDE9AALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1709009-B1 | 6-AMINO-5-CYANO-PYRIMIDINE-4-ONES USED FOR IMPROVING PERCEPTION, POWER OF CONCENTRATION, LEARNING EFFICIENCY, AND/OR MEMORY POWER | BOEHRINGER INGELHEIM INT (DE) | 2013-11-20 | — | — | EP | disclosed |
| US-8431573-B2 | Cyanopyrimidinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-30 | — | — | US | disclosed |
| US-8431573-B2 | Cyanopyrimidinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-30 | — | — | US | disclosed |
| US-8431573-B2 | Cyanopyrimidinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-30 | — | — | US | disclosed |
| US-8088769-B2 | e.g. 2-(3,4-Dichlorophenyl)ethanamidine hydrochloride; phosphodiesterases inhibitor; learning enhancement, cognition activator; improving perception, concentration, or memory | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-03 | — | — | US | disclosed |
| US-8088769-B2 | e.g. 2-(3,4-Dichlorophenyl)ethanamidine hydrochloride; phosphodiesterases inhibitor; learning enhancement, cognition activator; improving perception, concentration, or memory | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-03 | — | — | US | disclosed |
| US-8088769-B2 | e.g. 2-(3,4-Dichlorophenyl)ethanamidine hydrochloride; phosphodiesterases inhibitor; learning enhancement, cognition activator; improving perception, concentration, or memory | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-03 | — | — | US | disclosed |
| US-20110207735-A1 | CYANOPYRIMIDINONES | HENDRIX MARTIN | 2011-08-25 | — | — | US | disclosed |
| US-20110207735-A1 | CYANOPYRIMIDINONES | HENDRIX MARTIN | 2011-08-25 | — | — | US | disclosed |
| US-20110207735-A1 | CYANOPYRIMIDINONES | HENDRIX MARTIN | 2011-08-25 | — | — | US | disclosed |
| US-20080255118-A1 | Cyanopyrimidinones | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255118-A1 | Cyanopyrimidinones | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255118-A1 | Cyanopyrimidinones | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| WO-2006125554-A1 | USE OF CYANOPYRIMIDINES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2006-11-30 | — | — | WO | disclosed |
| WO-2005068436-A1 | 6-AMINO-5-CYANO-PYRIMIDINE-4-ONES USED FOR IMPROVING PERCEPTION, POWER OF CONCENTRATION, LEARNING EFFICIENCY, AND/OR MEMORY POWER | BAYER HEALTHCARE AG (DE) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255118-A1 | Cyanopyrimidinones | CACYBP, CHRM4, CHRNA4 | PNP 1449/4885PDE9A 280/4885ADORA2A 1084/4885 |
| US-20110207735-A1 | CYANOPYRIMIDINONES | CACYBP, CHRM4, CHRNA4 | PNP 1449/4885PDE9A 280/4885ADORA2A 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.